Zoghbi Huda Y 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Regeneron (REGN) Director Huda Y. Zoghbi Exercises Options, Sells Shares
What Happened
- Director Huda Y. Zoghbi exercised 1,638 stock options on Feb 19, 2026 at a strike of $376.69 per share (total cost $617,018). On the same day she sold multiple blocks of Regeneron (REGN) shares in open-market transactions, generating approximately $1,279,812 in proceeds.
- Transaction codes: M = option exercise (acquired shares), S = open-market sale (disposed). The exercise and same-day sales are often structured to cover exercise cost and taxes, but this summary only reports the facts.
Key Details
- Transaction date: February 19, 2026; Form 4 filed February 23, 2026 (timely within the 2-business-day window).
- Exercise: 1,638 shares @ $376.69 = $617,018 (reported as acquisition).
- Sales: multiple sales totaling ~1,279,812; sale prices ranged roughly from $774.68 to $790.00 (see footnotes for volume-weighted ranges per block).
- Footnotes of note:
- F1: Dispositions made pursuant to a Rule 10b5-1 trading plan adopted Nov 20, 2025.
- F10: The option vested in three equal annual installments beginning one year after grant.
- F2–F9: Provide VWAP ranges and note the reporting person will provide per-price breakdowns on request.
- Shares owned after the transactions are not provided in the excerpt of the filing.
Context
- This was an option exercise (derivative conversion) followed by open-market sales the same day. When exercised shares are sold immediately, it functionally resembles a cashless exercise—proceeds often cover strike price and taxes—but this report only confirms the exercise and sales, not the insider’s intent.
- Sales executed under a 10b5-1 plan are pre-arranged trades intended to avoid opportunistic timing; such plans are common for directors and officers and do not by themselves indicate a change in sentiment.
Insider Transaction Report
Form 4
Zoghbi Huda Y
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-19$376.69/sh+1,638$617,018→ 3,341 total - Sale
Common Stock
[F1]2026-02-19$774.68/sh−49$37,959→ 3,292 total - Sale
Common Stock
[F1]2026-02-19$775.50/sh−50$38,775→ 3,242 total - Sale
Common Stock
[F1][F2]2026-02-19$778.47/sh−53$41,259→ 3,189 total - Sale
Common Stock
[F1][F3]2026-02-19$779.55/sh−208$162,146→ 2,981 total - Sale
Common Stock
[F1][F4]2026-02-19$780.45/sh−331$258,329→ 2,650 total - Sale
Common Stock
[F1][F5]2026-02-19$781.28/sh−209$163,288→ 2,441 total - Sale
Common Stock
[F1][F6]2026-02-19$782.10/sh−298$233,066→ 2,143 total - Sale
Common Stock
[F1][F7]2026-02-19$783.29/sh−220$172,324→ 1,923 total - Sale
Common Stock
[F1][F8]2026-02-19$784.45/sh−160$125,512→ 1,763 total - Sale
Common Stock
[F1][F9]2026-02-19$785.61/sh−56$43,994→ 1,707 total - Sale
Common Stock
[F1]2026-02-19$790.00/sh−4$3,160→ 1,703 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F1][F10]2026-02-19−1,638→ 800 totalExercise: $376.69Exp: 2027-01-03→ Common Stock (1,638 underlying)
Footnotes (10)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
- [F10]The stock option vested in three equal annual installments, commencing one year after the date of grant.
- [F2]Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F3]Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F4]Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F5]Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F6]Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F7]Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F8]Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
- [F9]Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
Signature
/s/ Huda Y. Zoghbi|2026-02-23